Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $433000.0.

  • Editas Medicine's Capital Expenditures fell 8517.63% to $433000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 8866.88%. This contributed to the annual value of $8.8 million for FY2024, which is 8703.12% up from last year.
  • Latest data reveals that Editas Medicine reported Capital Expenditures of $433000.0 as of Q3 2025, which was down 8517.63% from $114000.0 recorded in Q1 2025.
  • In the past 5 years, Editas Medicine's Capital Expenditures ranged from a high of $3.5 million in Q2 2024 and a low of $114000.0 during Q1 2025
  • Its 5-year average for Capital Expenditures is $1.5 million, with a median of $1.3 million in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 112217.57% in 2024, then tumbled by 9390.7% in 2025.
  • Editas Medicine's Capital Expenditures (Quarter) stood at $2.8 million in 2021, then tumbled by 78.07% to $624000.0 in 2022, then skyrocketed by 109.46% to $1.3 million in 2023, then crashed by 58.68% to $540000.0 in 2024, then decreased by 19.81% to $433000.0 in 2025.
  • Its Capital Expenditures stands at $433000.0 for Q3 2025, versus $114000.0 for Q1 2025 and $540000.0 for Q4 2024.